MDA 19 (Standard)
MDA 19 (Standard) is the analytical standard of MDA 19. This product is intended for research and analytical applications. MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a Ki of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98%
- CAS 番号: 1048973-47-2
- 分子式: C21H23N3O2
- 分子量:349.43
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
化学情報
- 純度とドキュメンテーション
-
Help & FAQs
-
HY-15443
AM251CB1 Receptor Antagonist -
HY-15451
MDA 19CB2 Agonist -
HY-13439
SR144528CB2 Receptor Antagonist -
HY-10013
TaranabantCB1 Receptor Invert Agonist -
HY-18697
JD-5037CB1 Receptor Antagonist -
HY-10871
OtenabantCannabinoid Receptor Antagonist -
HY-14167
GW842166XCannabinoid Receptor Agonist -
HY-13288
Org 27569Cannabinoid Receptor Modulator -
HY-14791A
(±)-IbipinabantCannabinoid Receptor Antagonist -
HY-15420
BML-190Cannabinoid Receptor Agonist -
HY-16642A
LY2828360 -
HY-100488
Bay 59-3074CB1/CB2 Receptor Agonist
Product Information
説明
アプリケーション
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
化学情報
-
CAS 番号 1048973-47-2
-
分子量 349.43
-
分子式 C21H23N3O2
-
SMILES
O=C(C1=CC=CC=C1)N/N=C2C(N(C3=C\2C=CC=C3)CCCCCC)=O
-
別名
BZO-HEXOXIZID (Standard)
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Diaz, Philippe; Xu, Jijun; Astruc-Diaz, Fanny et al. Design and Synthesis of a Novel Series of N-Alkyl Isatin Acylhydrazone Derivatives that Act as Selective Cannabinoid Receptor 2 Agonists for the Treatment of Neuropathic Pain. Journal of Medicinal Chemistry (2008), 51(16), 4932-4947. [Content Brief]
[2]. Xu JJ, Diaz P, Astruc-Diaz F et al. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesth Analg. 2010 Jul;111(1):99-109. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
MDA 19 (Standard) 関連分類
HY-15451R 関連分類
Powered by Bioz